Skip to content
OpenCapital
Get started

Emergent Biosolutions EBS Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

CorMedix logo
CorMedixCRMD
$3.55M—

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×—
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%—

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's fair value adjustment of warrants?
Emergent Biosolutions (EBS) reported fair value adjustment of warrants of -$8.4M in Q1 2026.
How has Emergent Biosolutions's fair value adjustment of warrants changed year-over-year?
Emergent Biosolutions's fair value adjustment of warrants increased by 11.6% year-over-year, from -$9.5M to -$8.4M.
What does fair value adjustment of warrants mean?
Reflects the non-cash periodic adjustment to the fair value of outstanding warrants issued by the company. Fluctuations are typically driven by changes in the company's stock price and volatility assumptions used in valuation models. This metric helps investors understand the impact of derivative financial instruments on reported net income.